Why did PTC Therapeutics (PTCT) stock move recently?

On 8/25/2026, PTC Therapeutics moved +3.4% — PTCT rose on positive momentum from new Sephience (sepiapterin) clinical and real-world data reinforcing benefits in PKU patients, announced Aug 24 and featured at the SSIEM Symposium starting Aug 25, plus reported institutional buying including a large purchase by Parkman Healthcare Partners. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is PTC Therapeutics (PTCT) overvalued or fairly valued?

MarketChacha shows PTC Therapeutics's valuation in context — a trailing P/E of about 266.5, a forward P/E of about 27.8 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is PTC Therapeutics's revenue?

PTC Therapeutics reported revenue of $1.7B for FY2025, with net profit of $682.6M, per official filings.

What is the share price of PTC Therapeutics (PTCT)?

PTC Therapeutics last traded at $69.30 (-2.9% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

PTC Therapeutics

PTCT · NYSE · Healthcare · United States

Snapshot

TickerPTCT

ExchangeNYSE

SectorHealthcare

IndustryBiotechnology

CountryUnited States

Employees991

HeadquartersWarren, United States

Websitewww.ptcbio.com

Filings tracked22

About PTC Therapeutics

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Who owns it

Insiders7.3%
Institutions92.7%
Public & other0.0%

528 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.16.73%
RTW Investments LP9.28%
Jupiter Topco LLC8.67%
Vanguard Portfolio Management LLC5.90%
State Street Corporation5.51%
Wellington Management Group, LLP4.95%
Vanguard Capital Management LLC4.48%
Geode Capital Management, LLC2.64%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend-66.8% → 39.4%

Margin has expanded by about 106.3 points — the business is getting more profitable.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $319.6M · EPS 0.25

Est. earnings growth +113.7%

Next fiscal year

Rev $1.4B · EPS 2.50

Est. earnings growth +56.6%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$1.7B

Net margin

39.4%

Revenue CAGR (2y)

+35.8%

EPS (FY2025)

7.78

Net profit (FY2025)

$682.6M

Ask MarketChacha about PTCT

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Aug 25, 2026
PTCT rose on positive momentum from new Sephience (sepiapterin) clinical and real-world data reinforcing benefits in PKU patients, announced Aug 24 and featured at the SSIEM Symposium starting Aug 25, plus reported institutional buying including a large purchase by Parkman Healthcare Partners.
source 1 ↗source 2 ↗· confidence: medium

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin
FY2025	$1.7B	$682.6M	7.78	39.4%
FY2024	$806.8M	$-363.3M	-4.73	-45.0%
FY2023	$937.8M	$-626.6M	-8.37	-66.8%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$360.5M	$83.5M	0.92	23.2%
2026Q1	$272.6M	$-2.8M	-0.03	-1.0%
2025Q3	$211.0M	$15.9M	0.20	7.5%
2025Q2	$178.9M	$-64.8M	-0.83	-36.3%
2025Q1	$1.2B	$866.6M*	10.04	—
2024Q3	$196.8M	$-106.7M	-1.39	-54.2%
2024Q2	$186.7M	$-99.2M	-1.29	-53.1%
2024Q1	$210.1M	$-91.6M	-1.20	-43.6%
2023Q3	$196.6M	$-133.0M	-1.76	-67.6%
2023Q2	$213.8M	$-198.9M	-2.66	-93.0%
2023Q1	$220.4M	$-139.0M	-1.88	-63.1%

* Net profit includes one-off / non-operating items (e.g. a settlement or accounting gain), so it doesn’t reflect operating performance — net margin is hidden for that period.

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Executive/director change, Reg FD disclosure, Exhibits
SEC7/30/2026material
10-Q filing
SEC7/30/2026
8-K — Material agreement, Material financial obligation, Unregistered equity sale, Other events, Exhibits
SEC6/18/2026material
8-K — Other events, Exhibits
SEC6/16/2026material
8-K — Executive/director change, Exhibits
SEC6/9/2026material
8-K — Shareholder vote results
SEC6/5/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC5/7/2026material
10-Q filing
SEC5/7/2026
8-K — Reg FD disclosure, Exhibits
SEC4/28/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC3/25/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC2/19/2026material
10-K filing
SEC2/19/2026
8-K — Reg FD disclosure, Exhibits
SEC2/12/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC1/12/2026material

2025

8-K — Material agreement
SEC12/29/2025material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC11/4/2025material
10-Q filing
SEC11/4/2025
8-K — Reg FD disclosure, Exhibits
SEC8/19/2025material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC8/7/2025material
8-K — Material agreement
SEC8/7/2025material
10-Q filing
SEC8/7/2025
8-K — Reg FD disclosure, Exhibits
SEC7/28/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.